Go Pro
NASDAQ:FEMY

Femasys Q2 2026 Earnings Report

Femasys logo
$3.01 -0.04 (-1.31%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$3.02 +0.01 (+0.17%)
As of 07/17/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Femasys EPS Results

Actual EPS
N/A
Consensus EPS
-$1.27
Beat/Miss
N/A
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.73 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Friday, August 7, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Femasys Earnings Headlines

Trump’s emergency dollar reset
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this century — and the consequences for your savings and investments could be severe. President Trump has signed executive order 14241 to initiate the first full reset of the American dollar in 50 years. A new monetary anchor is being established — one that's not gold or crypto, but something far more unexpected that Vladimir Putin once called the key to world leadership.tc pixel
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY) International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools.

Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.

View Femasys Profile